Immunoenzymatic changes in ischemic stroke in children
Close
Articolul precedent
Articolul urmator
295 7
Ultima descărcare din IBN:
2022-05-30 22:48
Căutarea după subiecte
similare conform CZU
577.15:616.8-005.1-053.2 (1)
Material bases of life. Biochemistry. Molecular biology. Biophysics (664)
Neurology. Neuropathology. Nervous system (971)
SM ISO690:2012
SPRINCEAN, Mariana, HADJIU, Svetlana, LUPUŞOR, Nadejda, GRÎU, Corina, CUZNETZ, Ludmila, RACOVIȚĂ, Stela, FEGHIU, Ludmila, CĂLCÎI, Cornelia, REVENCO, Ninel, GROPPA, Stanislav. Immunoenzymatic changes in ischemic stroke in children. In: 7th Congress of the Society of Neurologists Issue of the Republic of Moldova, Ed. 7, 16-18 septembrie 2021, Chişinău. Chişinău: Revista Curier Medical, 2021, Vol.64, p. 25. ISSN 2537-6381 (Online).
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
7th Congress of the Society of Neurologists Issue of the Republic of Moldova
Vol.64, 2021
Congresul "7th Congress of the Society of Neurologists Issue of the Republic of Moldova"
7, Chişinău, Moldova, 16-18 septembrie 2021

Immunoenzymatic changes in ischemic stroke in children

CZU: 577.15:616.8-005.1-053.2

Pag. 25-25

Sprincean Mariana12, Hadjiu Svetlana1, Lupuşor Nadejda1, Grîu Corina1, Cuznetz Ludmila1, Racoviță Stela1, Feghiu Ludmila13, Călcîi Cornelia12, Revenco Ninel12, Groppa Stanislav13
 
1 ”Nicolae Testemițanu” State University of Medicine and Pharmacy,
2 Institute of Mother and Child,
3 Emergency Institute of Medicine
 
 
Disponibil în IBN: 27 septembrie 2021


Rezumat

Background: Ischemic stroke (IS) in children is a major neurological emergency, being a primary cause of morbidity and mortality. The incidence of IS is 2 – 13:100000 children or 1:4000 in neonatal period. The purpose of the study was evaluation of the expressivity of immune parameters in children with IS to improve understanding of pathogenesis, early diagnosis and predictive factors of the disease. Material and methods: In 2017 − 2019 in the Republic of Moldova a prospective study was carried out on a sample of 53 children with IS (study sample, SS), investigated by ELISA in the acute phase of the process determining the serum levels of endogline CD105 (ENG), S100B protein, vascular endothelial growth factor (VEGF), ciliary neurotrophic factor (CNTF), antiphospholipid antibodies (APA), and interleukin 6 (IL-6). These markers were also appreciated in 53 ”practically healthy” children (control sample, CS). Six months after IS, serum levels of VEGF and S100B were re-assessed. Results: Medium values of markers in acute phase were as follows: (1) ENG – 2.06 ± 0.012 ng/ml (F=84.812, p<0.001); (2) S-100B – 0.524 ± 0.0850 ng/ml (F=9.330, p<0.01); (3) VEGF – 613.41 ± 39.299 pg/ml (F=60.701, p<0.001); (4) CNTF – 7.84 ± 0.322 pg/ml (F=32.550, p<0.001); (5) APA –1.37 ± 0.046 U/ml (F=60.701, p<0.001); (6) IL-6 – 22.02 ± 2.143 pg/ml (F=43.810, p<0.001), which were significantly different from the levels in CS. Conclusions: During the acute period of stroke in children, an increased serum level of the protein S100B, VEGF, CNTF, APA and IL-6 is observed, while CD 105 has low levels. These changes can have predictive role to improve prognosis of neurological outcome.

Cuvinte-cheie
biomarkers, stroke, children